Gilead Sciences, Inc. (ETR:GIS)

Market Cap	132.85B
Revenue (ttm)	24.79B
Net Income (ttm)	6.91B
Shares Out	n/a
EPS (ttm)	5.47
PE Ratio	19.22
Forward PE	14.81
Dividend	2.82 (2.65%)
Ex-Dividend Date	Sep 15, 2025

Volume	494
Average Volume	984
Open	106.46
Previous Close	106.78
Day's Range	105.70 - 107.02
52-Week Range	81.29 - 111.84
Beta	0.33
RSI	65.41
Earnings Date	Oct 30, 2025

About Gilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1987
• Employees: 17,600
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: GIS

Financial Performance

In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.

Financial numbers in USD